Aiming for the cure in myeloma: Putting our best foot forward
Source : https://www.sciencedirect.com/science/article/abs/pii/S0268960X23000772?via=ihub
Frontline therapy for multiple myeloma (MM) is evolving to include novel combinations that can achieve unprecedented deep response rates. Several trea...
Conclusions/Relevance: This review analyzes the current relevant literature in upfront therapy for fit myeloma patients and provides suggestions for treatment approach while novel clinical trials are maturing.
Chimeric antigen receptor T cells: immunotherapy for the treatment of leukemia, lymphoma and myeloma.
Abstract. In immunotherapy with T cells genetically modified to express chimeric antigen receptors (CARs), autologous lymphocytes are extracted from the patient, genetically modified to obtain CAR-T cells, and reintroduced into...
Relevance: The aim of this review is to present the development of the structure of CAR-T cells, the therapies approved to date, the toxicity associated with them, and the advantages and limitations that they present as immunotherapy.
Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37568823/
Multiple myeloma (MM) frequently induces persisting osteolytic manifestations despite hematologic treatment response. This study aimed to establish a biometrically valid study endpoint for bone remineralization through quantitative and qualitative analyses...
Conclusions/Relevance: The sum of osteolytic lesion sizes on sequential CT scans defines a reliable study endpoint to characterize bone remineralization. Patient level response is strongly associated with the presence of trabecular sclerosis.
Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37573150/
This study shows that the incidence of infections and TRM are higher in MM patients from lower-middle income countries after AHCT than in those from developed countries. The majority of...
Conclusion: This study shows that the incidence of infections and TRM are higher in MM patients from lower-middle income countries after AHCT than in those from developed countries. The majority of such patients lack clinical localization and microbiological proof of infection. There was no significant difference in the spectrum of infections...
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37509726/
Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients typically experience bone pain, kidney...
Conclusions/Relevance: Recent advancements also involve monoclonal antibodies targeting surface antigens, such as elotuzumab (anti-CS1) and daratumumab (anti-CD38), bispecific t-cell engagers such as teclistamab (anti-BCMA/CD3) and Chimeric antigen receptor T (CAR-T)-based strategies, with a growing focus on drugs that exhibit increasingly...